FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment

[News]

Celsion Corporation, a leading oncology drug development company, today announced that the U.S. Food and Drug Administration has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation, as a Fast Track Development Program.

More... (http://www.news-medical.net/news/20100825/FDA-grants-Fast-Track-Designation-to-Celsions-ThermoDox-for-liver-cancer-treamtment.aspx)